In myeloma cells, GR binding could lead to a mutually exclusive expression of BCL2L11 and CXCR4, and provides new insights into the mechanisms of drug escape, although considering that GR levels can be a limiting event in Dex treatment (Heuck et al, 2012; Kervoëlen et al, 2015). Here, BCL2L11 is linked to plasma cell myeloma.